CME 2026 ASLMS 45th Annual Conference Recordings - Skin of Color: Best Practices for Lasers and EBD
The course was recorded on May 8, 2026, at the ASLMS Annual Conference.
Course Description: Medical lasers and energy-based devices are relatively under-utilized on patients with skin of color due to concerns regarding risk of pigmentary and other complications in Fitzpatrick skin phototypes IV-VI.
Medical lasers and energy-based devices can be used safely and effectively to treat a range of dermatologic concerns in patients with skin of color.
Careful selection of device type, settings, pre-and post-procedure precautions are key to optimizing outcomes for energy-based treatments in skin of color.
COURSE DIRECTORS: Andrew Alexis, MD, MPH; Keyvan Nouri, MD, MBA
FACULTY PANELISTS: Eliot F. Battle, Jr., MD – CEO & Co-Founder, Cultura Dermatology & Plastic Surgery; Henry Hin Lee Chan, MD, PhD, FRCP – Hon Clinical Professor, University of Hong Kong; Andrew Alexis, MD, MPH – Vice Chair, Weill Cornell Medicine; Mukta B. Sachdev, MD(Derm) DD,DPD,DipDerm (UK) – Medical Director, MS Skin Centre; Hye Jin Chung, MD, MMSc – Associate Professor, Beth Israel Deaconess Medical Center, Boston, MA; Harvard Medical School, Boston MA
LEARNING OBJECTIVES:
At the end of the activity, learners should be able to:
- Discuss optimal approaches to utilizing medical lasers and energy-based devices in patients with skin of color.
- Identify safe and effective devices and treatment parameters for addressing dermatologic concerns in patients with skin of color.
TARGET AUDIENCE:
This activity is intended for an audience of physicians and other healthcare professionals interested in the use of lasers, light, energy-based devices, and related technologies across various specialties.
PRESENTATIONS:
The Art and Science of Treating Skin of Color with Lasers and Energy-based Devices | Eliot F. Battle, Jr., MD – CEO & Co-Founder, Cultura Dermatology & Plastic Surgery
Picosecond Laser and Nanosecond Laser Treatment of Pigmented Lesions in East Asian Populations | Henry Hin Lee Chan, MD, PhD, FRCP – Hon Clinical Professor, University of Hong Kong
Broad Applications of Lasers in the Management of Common Dermatologic Disorders in Skin of Color (Case Based) | Andrew Alexis, MD, MPH – Vice Chair, Weill Cornell Medicine
Treatment of Melasma and other Hyperpigmentation Disorders in South Asian Populations | Mukta B. Sachdev, MD(Derm) DD,DPD,DipDerm (UK) – Medical Director, MS Skin Centre
Laser/EBD Treatment Pearls for Acne Scarring and more! (Case Based) | Hye Jin Chung, MD, MMSc – Associate Professor, Beth Israel Deaconess Medical Center, Boston, MA; Harvard Medical School, Boston MA
DISCLOSURES:
The American Society for Laser Medicine and Surgery (ASLMS) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by ASLMS are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by ASLMS in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by ASLMS to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by ASLMS.
All planners and faculty for this educational activity, except for those listed below, have no financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
- Keyvan Nouri, MD, MBA discloses the following financial relationships: iVeena Delivery Eye Drug Delivery systems: Bought with my own funds, Stock Shareholder (Individual stocks; diversified mutual funds do not need to be disclosed); Pfizer: Bought with my own funds, Stock Shareholder (Individual stocks; diversified mutual funds do not need to be disclosed)
- Andrew Alexis, MD, MPH discloses the following financial relationships: AbbVie: Consulting Fees (e.g., advisory boards), Contracted Research (Principal Investigators must provide information, even if received by the institution); Aerolase: Equipment, Speakers' Bureau; Allergan: Consulting Fees (e.g., advisory boards); Almirall: Consulting Fees (e.g., advisory boards); Alphyn: Consulting Fees (e.g., advisory boards); Alumis: Consulting Fees (e.g., advisory boards); Amgen: Consulting Fees (e.g., advisory boards), Contracted Research (Principal Investigators must provide information, even if received by the institution); Apogee: Consulting Fees (e.g., advisory boards); Arcutis: Consulting Fees (e.g., advisory boards), Grants (funds to institution); Bausch Health: Consulting Fees (e.g., advisory boards); Beiersdorf: Consulting Fees (e.g., advisory boards); BMS: Consulting Fees (e.g., advisory boards), Speakers' Bureau; Boehringer Ingelheim: Consulting Fees (e.g., advisory boards); Botanix: Consulting Fees (e.g., advisory boards); Canfield: Consulting Fees (e.g., advisory boards); Castle: Consulting Fees (e.g., advisory boards), Grants (funds to institution); Dermavant: Consulting Fees (e.g., advisory boards), Grants (funds to institution); Eli Lily: Consulting Fees (e.g., advisory boards); Elsevier: Royalty/Patent Beneficiary; Galderma: Consulting Fees (e.g., advisory boards), Grants (funds to institution); Genentech: Consulting Fees (e.g., advisory boards); HairDays: Consulting Fees (e.g., advisory boards); Incyte: Consulting Fees (e.g., advisory boards); Janssen: Consulting Fees (e.g., advisory boards), Speakers' Bureau; Johnson & Johnson: Speakers' Bureau; Leo Pharma: Consulting Fees (e.g., advisory boards), Grants (funds to institution); L'Oreal: Consulting Fees (e.g., advisory boards), Speakers' Bureau; Novartis: Consulting Fees (e.g., advisory boards); Ortho: Consulting Fees (e.g., advisory boards); Pfizer: Consulting Fees (e.g., advisory boards); Regeneron: Consulting Fees (e.g., advisory boards), Speakers' Bureau; Sanofi-Genzyme: Speakers' Bureau; Sanofi-Regeneron: Consulting Fees (e.g., advisory boards); Springer: Royalty/Patent Beneficiary; Swiss American: Consulting Fees (e.g., advisory boards); Symrise: Consulting Fees (e.g., advisory boards); UCB: Consulting Fees (e.g., advisory boards); VisualDX: Consulting Fees (e.g., advisory boards); Wiley-Blackwell: Royalty/Patent Beneficiary; Wolters Kluwer Health: Royalty/Patent Beneficiary Kristen M. Kelly, MD discloses the following financial relationships: Bausch Health: Investigator; MundiPharma, Allergan, Syneron Candela, Light Sciences Oncology, Novartis, Sciton, and ThermiRF: Consulting Fees (e.g., advisory boards) (Ongoing), Honoraria (Ongoing)
- Henry Hin Lee Chan, MD, PhD, FRCP discloses the following financial relationships: AbbVie Inc: Honoraria; AVAVA, LLC: Royalty/Patent Beneficiary, Stock Options Holder, Support Clinical Trial; Blossom Innovations, LLC: Royalty/Patent Beneficiary, Stock Options Holder; Boehringer Ingelheim (HK) Ltd: Honoraria; Clarity Cosmetics Inc: Stock Options Holder; Cutera, Inc: Support Clinical Trial; Cynosure, Inc.: Honoraria, Support Clinical Trial; Cytrellis Biosystems, Inc.: Stock Options Holder; Eli Lilly Asia Inc: Honoraria; Kyowa Kirin Asia Pacific Pte Ltd: Honoraria; Massachusetts General Hospital: Employee, Royalty/Patent Beneficiary; McGraw-Hill Companies: Royalty/Patent Beneficiary; R2 Dermatology, Inc in San Ramon, CA, USA: Royalty/Patent Beneficiary, Stock Options Holder, Support Clinical Trial (consumable only); SofWave Medical Ltd.: Honoraria, Support Clinical Trial; Solta Medical HK Ltd: Honoraria; UCB Pharma (Hong Kong) Ltd: Honoraria
- Hye Jin Chung, MD, MMSc discloses the following financial relationships: Recens Medical: Research Funding; Sonoma pharmaceutical: Consulting Fees (e.g., advisory boards)
- ASLMS staff planners and reviewers have no relevant financial relationships to disclose.
ACCME Accreditation Statement:
The American Society for Laser Medicine and Surgery, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement:
The American Society for Laser Medicine and Surgery, Inc. designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credits:
This enduring material is eligible for 1.8 CE credits if you are a Registered Nurse. These credits are provided with co-sponsorship with the Laser Training Institute division of Professional Medical Education Association.
Instructions for Learners to Receive Credit:
To receive a Certificate of Credit or a Certificate of Participation for the On-Demand (2026) course, registered attendees must submit a completed electronic CME/CE evaluation by the course expiration date (11/30/26).
This course should take approximately 1.5 hours to complete.
REFUND/CANCELLATION POLICY:
For questions related to claiming CME or CE credits, please contact education1@aslms.org or call (715) 845-9283.
- Refund requests will only be considered if made within 14 days of purchase.
- Refunds will only be considered if you have not yet started the course (no content viewed).
- Refunds are not available for missed live activities.
- Contact information@aslms.org to request a refund.
CONTACT INFORMATION:
For questions related to claiming CME or CE credits, please contact education1@aslms.org or call (715) 845-9283.
DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
DISCLOSURE OF OFF-LABEL USE:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The American Society for Laser Medicine & Surgery does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
Andrew Alexis, MD, MPH (Moderator)
Professor of Clinical Dermatology
Weill Cornell Medical College
Andrew F. Alexis, MD, MPH is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. He is the former Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color.
Dr. Alexis received his medical degree from Columbia University Vagelos College of Physicians & Surgeons and his Master of Public Health at Columbia University Mailman School of Public Health. He completed his dermatology residency at Weill Cornell Medicine, followed by a fellowship in dermatopharmacology at NYU Langone’s Ronald O. Perelman Department of Dermatology.
Dr. Alexis has published more than 100 articles in peer-reviewed journals including the British Journal of Dermatology, Journal of the American Academy of Dermatology, and JAMA Dermatology among others. He has co-edited two textbooks and authored over 10 book chapters. Dr. Alexis is a frequent lecturer at national and international conferences and has been invited as a Visiting Professor or Grand Rounds speaker at many prestigious academic institutions.
Dr. Alexis has held numerous leadership positions in professional organizations including Past President of the New York Dermatological Society, Past President of the New York Academy of Medicine Dermatology Section, Secretary/Treasurer of the Skin of Color Society and Chair of the Diversity Task Force Committee for the American Academy of Dermatology. He currently serves as President of the Skin of Color Society and is a member of the Board of Directors of the Scarring Alopecia Foundation.
Dr. Alexis has appeared on ABC, CBS, NBC, and FOX television news programs and has been quoted in numerous leading publications, including the New York Times, Wall Street Journal, Forbes, Vogue, Allure, and Essence. He is listed in Castle Connolly’s Top Doctors ™ and Super Doctors®.
Keyvan Nouri, MD, MBA (Moderator)
Department of Dermatology and Cutaneous Surgery, University of Miami Leonard M. Miller School of Medicine, Miami, FL, USA
Eliot Battle, MD
CEO & co-founder
Cultura Dermatology & Plastic Surgery
Dr. Eliot F. Battle, Jr. is the CEO and co-founder of Cultura Dermatology & Plastic Surgery. Cultura’s groundbreaking center, located in Washington, DC, is an important destination for patients from all over the world as well as physicians seeking advance training.
Dr. Battle’s did his research and clinicaal fellowship at Harvard’s Wellman laboratories of Photomedicine and was one of the researchers involved in pioneering the use of lasers on skin of color, opening the field to patients of all cultures, regardless of skin of color or ethnicity.
Dr. Battle's numerous national academic honors and awards, which include induction into Alpha Omega Alpha medical honor society, recognition as a National Institute of Health research scholar, awarded the Innovations in Skin of Color Dermatology Award and has been the co-chair of the Skin of Color Update conference for the last 14-years.
Dr. Battle is a member of the American Academy of Dermatology, American Society of Laser Medicine & Surgery, and numerous International Societies. He is a past-Chairman of the Dermatology Section of the National Medical Association and the past-President of the Howard University Medical Alumni Association. Dr. Battle and his center have also been awarded numerous business awards including Emerging Business of the Year Award and the Business Leader Award.
Henry Chan, MD, PhD, FRCP
Hon Clinical Professor
University of Hong Kong
Brief CV of Dr Chan Henry Hin Lee
MBBS (Lond), MD (Lond), M Sc (Clinical Dermatology)(Lond), PhD (HK),
MRCP (UK), FRCP (Lond, Edin, Glasg), FHKCP, FHKAM (Medicine)
Dr Henry Chan is a specialist in dermatology and venereology. He is also currently the Honorary Clinical Professor of the Division of Dermatology, Department of Medicine, the University of Hong Kong and Honorary Consultant Dermatologist of Queen Mary Hospital.
Dr Chan was the chief of the dermatology division of both the University of Hong Kong (Associate Professor 2000 – 2004) and The Chinese University of Hong Kong (Associate Professor 1998 – 2000). He was the President of the Hong Kong College of Dermatologists (2009 – 2013) and the Honorary Secretary of the Asian Dermatological Association (1999 – 2011). He was also the Chairman of the Hong Kong Society of Dermatology and Venereology (2003 – 2005 & 2007 – 2009). Dr Chan has published or accepted to be published over 370 articles including 1 book, 37 book chapters and 153 peer reviewed international indexed publications (mean impact factor 4.148, total citation 4,319 and H Index: 41 (researcher ID number: L-2267-2013; ORCID number: 0000-0002-9657-1435). He is the Associate Editor of Lasers in Surgery and Medicine and serves on the editorial board of other international journals including the Dermatologic Surgery, Lasers in Medical Science and Archives of Dermatological Research.
Dr Chan obtained his Medical degree (MBBS) from The London Hospital Medical College, University of London, Master (M Sc Clinical dermatology) and his first Doctorate degree (MD), from King’s College, University of London. He then did his second Doctorate degree (PhD) from Li Ka Shing Faculty of Medicine, University of Hong Kong, part of his PhD was done at the Wellman Center for Photomedicine, Massachusetts General Hospital (MGH), a teaching affiliate of Harvard Medical School, Boston, USA. As a result, he has been a visiting faculty (research staff) at the Wellman Center, MGH since 2007 and was Visiting Associate Professor at Harvard Medical School from 2008 until 2010. Dr Chan’s work has led him to successfully obtained six patent families (five in Boston and one in Hong Kong). In 2011, he and 3 other colleagues (Dr Rox Anderson, Dr Dieter Manstein and Dr Irina Erenburg) at MGH, Harvard Medical School set up an incubator company known as Blossom Innovations and sub-licensed these technologies back from MGH for further development. Subsequently, these technologies have been transferred to R2 Dermatology in California and AVAVA LLC in Boston. He is a member of the Board of Director of Blossom Innovations, AVAVA and S3 Inject.
Dr Chan is the Past-President (2021-2022) of the American Society for Laser Medicine & Surgery (ASLMS, found in 1980, is the world largest Professional organization dedicated to promoting research, education and clinical care in the field of medical laser and energy-based applications). Dr Chan was the Conference Program Co-Chair for 2019 ASLMS annual conference in Denver. Dr Chan was elected as a member of the ASLMS Board of Directors (2012-2015) and re-elected again in 2018 (2018-2021). In 2010, Dr Chan was awarded the Ellet H Drake Memorial Award by ASLMS for his contribution to laser surgery. He was also the recipient of the ASLMS Presidential Citation in 2002, 2016 and 2018, ASLMS Best Session Award Clinical Applications – Cutaneous in 2018 and ASLMS Program Chair Recognition in 2019, ASLMS President’s Leadership Award in 2022 and Outstanding Service Award in 2023.
Dr Chan received the Presidential Award presented by the American Society for Dermatologic Surgery (ASDS) in 2014 and 2021. In 2020, Dr Chan was awarded by The Sturge-Weber Foundation as one of the honorees. In March 2016, Dr Chan was voted and elected by the membership of the American Dermatological Association as an International Honorary Member. He was also an elected board member of Dermatologic Aesthetic Surgery International League (DASIL) (2011-2014) and an Honorary President of its annual congress in 2017. His other professional associations include Fellowships of the following institutions: the Royal College of Physicians of London, the Royal College of Physicians of Edinburgh, the Royal College of Physicians and Surgeons of Glasgow, Hong Kong College of Physicians and Hong Kong Academy of Medicine (Medicine).
He is Council and Court member of the University of Hong Kong; Board of Director of Versitech Limited, the University of Hong Kong; Board of Director of Chinese University of Hong Kong Medical Center, and Member of Hospital Governing Committee of MacLehose Medical Rehabilitation Centre, Hospital Authority. He is a Steward of The Hong Kong Jockey Club.
Mukta Sachdev, MD, DDS
Head of Department of Dermatology
Manipal Hospital,Bangalore,India
Dr. Mukta Sachdev, MD in Dermatology with a Fellowship in Cosmetic Dermatology from Florida, USA, and Diplomas in Dermatology form the UK .
She is a Consultant Clinical and Aesthetic Dermatologist and Head of the Department of Dermatology at Manipal Hospital in Bangalore, India. Additionally, she operates a private boutique office practice at Cambridge Layout, Bangalore, and holds the role of Medical Director at MS Clinical Research, a dermatology-focused CRO. With over two decades of experience in dermatological practice, Dr. Sachdev is recognized as a Fellow of the American Academy of Dermatology (USA), the ASDS - American Society of Dermatologic Surgery, WDS, SOCS (International), as well as IADVL, ACSI, BDS (Indian), among other dermatological societies. Her extensive expertise in cosmetic dermatology, particularly in skin of color, has led to her global recognition as a Key Opinion Leader. Dr. Sachdev’s contributions extend to pioneering work in developing guidelines and protocols for the use of chemical peels and lasers in diverse skin types, collaborating with associations and industry partners. As the Medical Director of MSCR, she has been instrumental in more than 500 clinical and cosmeceutical studies. Dr. Mukta Sachdev’s combined experience and innovative approach make her a sought-after expert in the field .
In addition to her professional roles, Dr. Mukta Sachdev is a frequent speaker at international and national conferences and meetings, where she shares her expertise, publishes and presents data regularly, and has co-authored three textbooks on cosmetic dermatology in skin of color. Her commitment to advancing dermatological care and her innovative approach continue to make her a highly sought-after expert in the field.
Hye Jin Chung, MD, MMSc
Assistant Professor
Beth Israel Deaconess Medical Center, Boston, MA; Harvard Medical School, Boston, MA
Dr. Chung graduated with her MD from Yonsei University College of Medicine, Seoul, Korea in 2001, where she completed her residency and fellowship training in Dermatology. She finished her post-doctoral research fellowship and residency in dermatology at Thomas Jefferson University Hospital, Philadelphia in 2014 and completed her dermatopathology fellowship at Boston University, Boston in 2016. She is a dermatologist and dermatopathologist and runs Skin of Color/Asian Skin clinic at the Department of Dermatology, Beth Israel Deaconess Medical Center. Dr. Chung has done significant research in the field of scarring disorders, laser therapy, and dermatopathology. She has clinical interests in scar treatment, pigmentary disorders, Asian skin diseases, Skin of Color, and laser therapy.
Key:
Complete
Next
Failed
Available
Locked